Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.

Adult Aged Aged, 80 and over Aging / blood Antibodies, Neutralizing / blood Antibodies, Viral / blood Autoantibodies / immunology B-Lymphocytes / cytology BNT162 Vaccine COVID-19 Vaccines / administration & dosage Female Health Personnel Humans Immunity / genetics Immunization, Secondary Immunoglobulin A / immunology Immunoglobulin Class Switching Immunoglobulin G / genetics Immunologic Memory / immunology Inflammation / blood Interferon-gamma / immunology Interleukin-2 / immunology Male Middle Aged SARS-CoV-2 / immunology Somatic Hypermutation, Immunoglobulin Spike Glycoprotein, Coronavirus / immunology T-Lymphocytes / immunology Vaccination Vaccines, Synthetic / administration & dosage mRNA Vaccines

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
08 2021
Historique:
received: 16 04 2021
accepted: 18 06 2021
pubmed: 1 7 2021
medline: 25 8 2021
entrez: 30 6 2021
Statut: ppublish

Résumé

Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, there is little information about vaccine efficacy against variants of concern (VOC) in individuals above eighty years of age

Identifiants

DOI: 10.1038/s41586-021-03739-1 PMID: 34192737 PMC: PMC8373615
pubmed: 34192737
doi: 10.1038/s41586-021-03739-1
pii: 10.1038/s41586-021-03739-1
pmc: PMC8373615
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Autoantibodies 0
COVID-19 Vaccines 0
Immunoglobulin A 0
Immunoglobulin G 0
Interleukin-2 0
Spike Glycoprotein, Coronavirus 0
Vaccines, Synthetic 0
spike protein, SARS-CoV-2 0
Interferon-gamma 82115-62-6
BNT162 Vaccine N38TVC63NU

Types de publication

Comparative Study Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

417-422

Subventions

Organisme : Wellcome Trust
ID : 200871/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT108082AIA
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S00081X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R008698/1
Pays : United Kingdom

Investigateurs

Stephen Baker (S)
Gordon Dougan (G)
Christoph Hess (C)
Nathalie Kingston (N)
Paul J Lehner (PJ)
Paul A Lyons (PA)
Nicholas J Matheson (NJ)
Willem H Owehand (WH)
Caroline Saunders (C)
Charlotte Summers (C)
James E D Thaventhiran (JED)
Mark Toshner (M)
Michael P Weekes (MP)
Patrick Maxwell (P)
Ashley Shaw (A)
Ashlea Bucke (A)
Jo Calder (J)
Laura Canna (L)
Jason Domingo (J)
Anne Elmer (A)
Stewart Fuller (S)
Julie Harris (J)
Sarah Hewitt (S)
Jane Kennet (J)
Sherly Jose (S)
Jenny Kourampa (J)
Anne Meadows (A)
Criona O'Brien (C)
Jane Price (J)
Cherry Publico (C)
Rebecca Rastall (R)
Carla Ribeiro (C)
Jane Rowlands (J)
Valentina Ruffolo (V)
Hugo Tordesillas (H)
Ben Bullman (B)
Benjamin J Dunmore (BJ)
Stuart Fawke (S)
Stefan Gräf (S)
Josh Hodgson (J)
Christopher Huang (C)
Kelvin Hunter (K)
Emma Jones (E)
Ekaterina Legchenko (E)
Cecilia Matara (C)
Jennifer Martin (J)
Federica Mescia (F)
Ciara O'Donnell (C)
Linda Pointon (L)
Nicole Pond (N)
Joy Shih (J)
Rachel Sutcliffe (R)
Tobias Tilly (T)
Carmen Treacy (C)
Zhen Tong (Z)
Jennifer Wood (J)
Marta Wylot (M)
Laura Bergamaschi (L)
Ariana Betancourt (A)
Georgie Bower (G)
Chiara Cossetti (C)
Aloka De Sa (A)
Madeline Epping (M)
Stuart Fawke (S)
Nick Gleadall (N)
Richard Grenfell (R)
Andrew Hinch (A)
Oisin Huhn (O)
Sarah Jackson (S)
Isobel Jarvis (I)
Ben Krishna (B)
Daniel Lewis (D)
Joe Marsden (J)
Francesca Nice (F)
Georgina Okecha (G)
Ommar Omarjee (O)
Marianne Perera (M)
Martin Potts (M)
Nathan Richoz (N)
Veronika Romashova (V)
Natalia Savinykh Yarkoni (NS)
Rahul Sharma (R)
Luca Stefanucci (L)
Jonathan Stephens (J)
Mateusz Strezlecki (M)
Lori Turner (L)
Eckart M D D De Bie (EM)
Katherine Bunclark (K)
Masa Josipovic (M)
Michael Mackay (M)
Alice Michael (A)
Sabrina Rossi (S)
Mayurun Selvan (M)
Sarah Spencer (S)
Cissy Yong (C)
Ali Ansaripour (A)
Alice Michael (A)
Lucy Mwaura (L)
Caroline Patterson (C)
Gary Polwarth (G)
Petra Polgarova (P)
Giovanni di Stefano (G)
Codie Fahey (C)
Rachel Michel (R)
Sze-How Bong (SH)
Jerome D Coudert (JD)
Elaine Holmes (E)
John Allison (J)
Helen Butcher (H)
Daniela Caputo (D)
Debbie Clapham-Riley (D)
Eleanor Dewhurst (E)
Anita Furlong (A)
Barbara Graves (B)
Jennifer Gray (J)
Tasmin Ivers (T)
Mary Kasanicki (M)
Emma Le Gresley (E)
Rachel Linger (R)
Sarah Meloy (S)
Francesca Muldoon (F)
Nigel Ovington (N)
Sofia Papadia (S)
Isabel Phelan (I)
Hannah Stark (H)
Kathleen E Stirrups (KE)
Paul Townsend (P)
Neil Walker (N)
Jennifer Webster (J)

Informations de copyright

© 2021. The Author(s).

Références

Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439–2450 (2020).
doi: 10.1056/NEJMoa2027906
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
doi: 10.1056/NEJMoa2034577
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
doi: 10.1056/NEJMoa2035389
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med.  https://doi.org/10.1038/s41591-021-01377-8 (2021).
doi: 10.1038/s41591-021-01377-8 pubmed: 34002089
Israelow, B. et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Preprint at https://doi.org/10.1101/2021.05.19.444825 (2021).
Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Preprint at https://doi.org/10.1101/2021.06.21.21258528 (2021).
Department of Health. Briefing on Rescheduling of Second Doses of the Pfizer/BioNTech Covid-19 Vaccine https://www.health-ni.gov.uk/news/briefing-rescheduling-second-doses-pfizerbiontech-covid-19-vaccine (2021).
Volz, E. et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 593, 266–269 (2021).
doi: 10.1038/s41586-021-03470-x
Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 593, 136–141 (2021).
doi: 10.1038/s41586-021-03412-7
Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1885–1898 (2021).
doi: 10.1056/NEJMoa2102214
Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, e20201181 (2020).
doi: 10.1084/jem.20201181
Raybould, M. I. J., Kovaltsuk, A., Marks, C. & Deane, C. M. CoV-AbDab: the coronavirus antibody database. Bioinformatics 37, 734–735 (2021).
doi: 10.1093/bioinformatics/btaa739
Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583–588 (2020).
doi: 10.1038/s41586-020-2607-z
McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2021).
doi: 10.1038/s41586-020-03041-6
Merani, S., Pawelec, G., Kuchel, G. A. & McElhaney, J. E. Impact of aging and cytomegalovirus on immunological response to influenza vaccination and infection. Front. Immunol. 8, 784 (2017).
doi: 10.3389/fimmu.2017.00784
Kadambari, S., Klenerman, P. & Pollard, A. J. Why the elderly appear to be more severely affected by COVID-19: the potential role of immunosenescence and CMV. Rev. Med. Virol. 30, e2144 (2020).
doi: 10.1002/rmv.2144
Ray, D. & Yung, R. Immune senescence, epigenetics and autoimmunity. Clin. Immunol. 196, 59–63 (2018).
doi: 10.1016/j.clim.2018.04.002
Libster, R. et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N. Engl. J. Med. 384, 610–618 (2021).
doi: 10.1056/NEJMoa2033700
Anderson, E. J. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 383, 2427–2438 (2020).
doi: 10.1056/NEJMoa2028436
Li, J. et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat. Med. 27, 1062–1070 (2021).
doi: 10.1038/s41591-021-01330-9
Silva-Cayetano, A. et al. A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. Med 2, 243–262 (2020).
doi: 10.1016/j.medj.2020.12.006
Docherty, A. B. et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. Br. Med. J. 369, m1985 (2020)
doi: 10.1136/bmj.m1985
Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592, 277–282 (2021).
doi: 10.1038/s41586-021-03291-y
Mlcochova, P. et al. Combined point of care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G spike variant. Cell Rep Med 1, 100099 (2020).
doi: 10.1016/j.xcrm.2020.100099
Xiong, X. et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934–941 (2020).
doi: 10.1038/s41594-020-0478-5
Graham, C. et al. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity 54, 1276–1289.e6 (2021).
doi: 10.1016/j.immuni.2021.03.023

Auteurs

Dami A Collier (DA)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
Division of Infection and Immunity, University College London, London, UK.
ORCID: 0000-0001-5446-4423

Isabella A T M Ferreira (IATM)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Prasanti Kotagiri (P)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Rawlings P Datir (RP)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
Division of Infection and Immunity, University College London, London, UK.
ORCID: 0000-0003-0521-2144

Eleanor Y Lim (EY)

Department of Medicine, University of Cambridge, Cambridge, UK.

Emma Touizer (E)

Division of Infection and Immunity, University College London, London, UK.

Bo Meng (B)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Adam Abdullahi (A)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.

Anne Elmer (A)

NIHR Bioresource, Cambridge, UK.
Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Nathalie Kingston (N)

NIHR Bioresource, Cambridge, UK.
Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Barbara Graves (B)

NIHR Bioresource, Cambridge, UK.

Emma Le Gresley (E)

NIHR Bioresource, Cambridge, UK.
Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Daniela Caputo (D)

NIHR Bioresource, Cambridge, UK.
Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Laura Bergamaschi (L)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.

Kenneth G C Smith (KGC)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
ORCID: 0000-0003-3829-4326

John R Bradley (JR)

Department of Medicine, University of Cambridge, Cambridge, UK.
NIHR Bioresource, Cambridge, UK.

Lourdes Ceron-Gutierrez (L)

Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, Cambridge, UK.

Paulina Cortes-Acevedo (P)

Laboratorio de Inmunología, FES-Cuautitlán, UNAM, Mexico City, Mexico.

Gabriela Barcenas-Morales (G)

Laboratorio de Inmunología, FES-Cuautitlán, UNAM, Mexico City, Mexico.

Michelle A Linterman (MA)

Immunology Programme, Babraham Institute, Cambridge, UK.
ORCID: 0000-0001-6047-1996

Laura E McCoy (LE)

Division of Infection and Immunity, University College London, London, UK.
ORCID: 0000-0001-9503-7946

Chris Davis (C)

MRC Centre for Virus Research, University of Glasgow, Glasgow, UK.

Emma Thomson (E)

MRC Centre for Virus Research, University of Glasgow, Glasgow, UK.
ORCID: 0000-0003-1482-0889

Paul A Lyons (PA)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
ORCID: 0000-0001-7035-8997

Eoin McKinney (E)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK. efm30@medschl.cam.ac.uk.
Department of Medicine, University of Cambridge, Cambridge, UK. efm30@medschl.cam.ac.uk.

Rainer Doffinger (R)

Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK. rd270@medschl.cam.ac.uk.

Mark Wills (M)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK. mrw1004@cam.ac.uk.
Department of Medicine, University of Cambridge, Cambridge, UK. mrw1004@cam.ac.uk.

Ravindra K Gupta (RK)

Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK. rkg20@cam.ac.uk.
Department of Medicine, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk.
ORCID: 0000-0001-9751-1808

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Age-related immune response heterogeneity to...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Age-related immune response heterogeneity to...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Age-related immune response heterogeneity to...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Vieillissement › Age-related immune response heterogeneity to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Age-related immune response heterogeneity to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Age-related immune response heterogeneity to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Age-related immune response heterogeneity to...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes B › Age-related immune response heterogeneity to...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Vaccin BNT162 › Age-related immune response heterogeneity to...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Age-related immune response heterogeneity to...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Personnel de santé › Age-related immune response heterogeneity to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Age-related immune response heterogeneity to...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Age-related immune response heterogeneity to...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Rappel de vaccin › Age-related immune response heterogeneity to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline A › Age-related immune response heterogeneity to...
questionsmedicales.fr › Phénomènes du système immunitaire › Phénomènes immunogénétiques › Réarrangement des gènes des lymphocytes B › Réarrangement des gènes des chaines lourdes des lymphocytes B › Commutation de classe des immunoglobulines › Age-related immune response heterogeneity to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Isotypes des immunoglobulines › Immunoglobuline G › Age-related immune response heterogeneity to...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Mémoire immunologique › Age-related immune response heterogeneity to...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Age-related immune response heterogeneity to...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Lymphokines › Facteurs d'activation des macrophages › Interféron gamma › Age-related immune response heterogeneity to...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Lymphokines › Interleukine-2 › Age-related immune response heterogeneity to...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Age-related immune response heterogeneity to...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Age-related immune response heterogeneity to...
questionsmedicales.fr › Phénomènes du système immunitaire › Phénomènes immunogénétiques › Hypermutation somatique des gènes des immunoglobulines › Age-related immune response heterogeneity to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Age-related immune response heterogeneity to...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Age-related immune response heterogeneity to...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Age-related immune response heterogeneity to...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Age-related immune response heterogeneity to...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Age-related immune response heterogeneity to...